Retinoids are the gold standard in dermatology for cell turnover and collagen production. They are also among the most irritating ingredients available. The question is not whether retinoids work — they do. The question is whether the irritation is a necessary trade-off or a sign that a different approach is possible.
In our view, it is the latter.
How Retinoids Work
Retinoids — a class including retinol, retinaldehyde, and prescription tretinoin — bind to retinoic acid receptors (RARs) in the nucleus of skin cells. This binding triggers a cascade of gene expression changes. Retinoic acid responsive genes include those for collagen synthesis, cell cycle regulation, and epidermal differentiation.
The effect is powerful: accelerated cell turnover, increased collagen production, normalized follicular keratinization. But the mechanism is blunt. Retinoids upregulate hundreds of genes, many of which have nothing to do with the desired outcome. Among the upregulated genes are pro-inflammatory cytokines — IL-1α, IL-6, TNF-α — which produce the redness, peeling, and stinging that characterize the "retinoid reaction."
The Instability Problem
Beyond irritation, retinol presents a stability challenge that mirrors the vitamin C problem. Retinol is highly unstable in the presence of oxygen and light. It degrades into inactive and potentially irritating byproducts. In a traditional supply chain — warehouse to store to bathroom shelf — a retinol product may lose 30-50% of its potency before the consumer finishes the bottle.
Made-to-order production can partially address this by shortening the time between manufacture and use. But the inherent instability remains a formulation constraint that limits shelf life and forces packaging into opaque, airless systems.
Non-Retinoid Pathways to Turnover
Cell turnover is not controlled by a single pathway. Several signaling cascades regulate keratinocyte proliferation, differentiation, and desquamation. Targeting these alternative pathways can achieve meaningful turnover without the inflammatory cost of retinoids.
Polyhydroxy acids (PHAs) such as gluconolactone and lactobionic acid work through enzymatic desquamation and osmotic signaling. They loosen corneocyte adhesion without penetrating deep enough to trigger inflammation. The turnover effect is milder than retinol but cumulative and irritation-free.
Niacinamide (vitamin B3) increases keratinocyte differentiation and ceramide synthesis through a separate receptor pathway (GPR109A). It does not cause peeling or irritation at standard concentrations (2-5%), making it suitable for long-term use without a "retinoid reaction" phase.
Copper peptides (GHK-Cu) signal through the MAPK pathway to upregulate collagen synthesis and downregulate MMP expression. While not a direct cell turnover trigger, the effect on matrix remodeling produces visible improvement in texture and firmness over time.
Lactobacillus ferment extracts contain bioactive peptides and enzymes that influence cell signaling through toll-like receptor (TLR) pathways, promoting differentiation without inflammation. The effect is mild and cumulative, requiring consistent use over weeks rather than days.
The NeoLabCare Position
We do not use retinol. This is not a judgment on retinol users — the ingredient has decades of clinical data supporting its efficacy. Our position is that the irritation-stability complex represents a design constraint we choose not to accept.
Instead, we formulate with copper peptides, niacinamide, and PHAs in a made-to-order system that delivers each ingredient at peak potency. The result is slower to appear than retinol but does not require a three-month adjustment period of peeling and sensitivity. For customers who prefer retinol, we recommend it as a complement. Our formulation is designed to support the skin during and after retinoid therapy, not to replace it.
The goal is not to be anti-retinol. The goal is to offer a non-inflammatory path to skin health that works on its own terms.